Education
About Us
Working with TipRanks
Follow Us
Fuso Pharmaceutical Industries,Ltd. (JP:4538)
:4538
4538 Stock Chart & Stats
¥2315.00
-¥64.00(-2.54%)
At close: 4:00 PM EST
¥2315.00
-¥64.00(-2.54%)
Day’s Range― - ―
52-Week Range¥2,028.00 - ¥2,641.00
Previous CloseN/A
Volume28.90K
Average Volume (3M)17.49K
Market Cap
¥20.62B
Enterprise Value¥41.71B
Total Cash (Recent Filing)¥3.16B
Total Debt (Recent Filing)¥28.23B
Price to Earnings (P/E)―
Beta0.62
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.71%
Share Statistics
EPS (TTM)99.84
Shares Outstanding9,451,169
10 Day Avg. Volume18,340
30 Day Avg. Volume17,486
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.53
Price to Sales (P/S)0.34
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained revenue growth reflects steady demand for hospital-use pharmaceuticals and stronger product adoption in clinical channels. Over 2-6 months this trend supports predictable top-line expansion, underpins reinvestment capacity for manufacturing and R&D, and signals durable market traction.
Prudent Leverage / Strong Equity BaseA moderate debt-to-equity ratio and near-50% equity ratio indicate a stable balance sheet able to absorb shocks. This durable capital structure provides financial flexibility to fund capital expenditure, maintain operations during revenue cycles, and pursue strategic investments without over-reliance on volatile financing.
Improving Profitability MarginsHealthy gross margin and an improving net margin point to effective cost control and pricing power in hospital products. Over the medium term, these margin levels support operating viability, allow reinvestment into manufacturing or incremental R&D, and reduce sensitivity to modest revenue swings.
Bears Say
Negative Free Cash FlowPersistent negative free cash flow is a structural concern: it limits internal funding for capex, R&D, and dividends, and forces reliance on external financing. Over months this weakens liquidity flexibility, can raise funding costs, and constrains the company's ability to capitalize on growth opportunities.
Earnings Volatility / Negative EPS GrowthSevere negative EPS growth signals earnings instability that may reflect one-offs or operational pressures. Sustained volatility hampers long-term planning, investor confidence, and can increase the cost of capital, making it harder to fund strategic initiatives without dilutive or debt financing.
Moderate Operating MarginsModerate EBIT and EBITDA margins leave limited buffer versus cost inflation or pricing pressure in the specialty/generic drug market. Structurally, this reduces ability to convert revenue growth into cash, increasing sensitivity to input cost shocks and complicating efforts to repair negative cash flow without efficiency gains.
Fuso Pharmaceutical Industries,Ltd. News
4538 FAQ
What was Fuso Pharmaceutical Industries,Ltd.’s price range in the past 12 months?
Fuso Pharmaceutical Industries,Ltd. lowest stock price was ¥2028.00 and its highest was ¥2641.00 in the past 12 months.
What is Fuso Pharmaceutical Industries,Ltd.’s market cap?
Fuso Pharmaceutical Industries,Ltd.’s market cap is ¥20.62B.
When is Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date?
Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date is May 13, 2026 which is in 85 days.
How were Fuso Pharmaceutical Industries,Ltd.’s earnings last quarter?
Fuso Pharmaceutical Industries,Ltd. released its earnings results on Feb 12, 2026. The company reported ¥99.84 earnings per share for the quarter, beating the consensus estimate of N/A by ¥99.84.
Is Fuso Pharmaceutical Industries,Ltd. overvalued?
According to Wall Street analysts Fuso Pharmaceutical Industries,Ltd.’s price is currently Overvalued.
Does Fuso Pharmaceutical Industries,Ltd. pay dividends?
Fuso Pharmaceutical Industries,Ltd. pays a Semiannually dividend of ¥45 which represents an annual dividend yield of 3.71%. See more information on Fuso Pharmaceutical Industries,Ltd. dividends here
What is Fuso Pharmaceutical Industries,Ltd.’s EPS estimate?
Fuso Pharmaceutical Industries,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuso Pharmaceutical Industries,Ltd. have?
Fuso Pharmaceutical Industries,Ltd. has 9,451,169 shares outstanding.
What happened to Fuso Pharmaceutical Industries,Ltd.’s price movement after its last earnings report?
Fuso Pharmaceutical Industries,Ltd. reported an EPS of ¥99.84 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.465%.
Which hedge fund is a major shareholder of Fuso Pharmaceutical Industries,Ltd.?
Currently, no hedge funds are holding shares in JP:4538
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.
Technical Analysis
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---